Please assess the completion status of the following clinical trial:

Trial Title: Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 7 years followed in the 6 CRCM centers (Créteil, Marseille, Nantes, Toulouse, Clermont-Ferrand and Nice). We choose to enroll children aged 7 years or more because as they have a better adherence to nebulization treatment than younger children.~* Diagnosis of cystic fibrosis confirmed by sweat test (\>60mmol/L) and/or the identification of two CF-causing mutations~* Confirmed chronic rhinosinusitis by Ear Nose and Throat doctor by endoscopic examination: bilateral mucopurulent secretions at middle meatus present longer than 12 weeks with or without nasal polyps~* Positive bacteria susceptibility to tobramycin in samples from middle meatus~* Susceptibility of bacteria to tobramycin confirmed~* Pulmonary examination before enrollment~* Written informed consent obtained at enrollment for all patients (consent of minor's parent for children)~* Social security affiliation~Exclusion Criteria:~* - Oral antibiotic therapy one month before enrollment~* enrollment in another protocol with antibiotic~* Ongoing aerosolized tobramycin for endobronchial infection to avoid an overlap between treatment for lung and treatment for sinusitis~* Abnormal auditory acuity (decrease of 20dB in auditory acuity)~* Hypersensibility or allergenecity of aminoglycosides~* FEV \< 25% or FVC of 40% or more of the value predicted for height~* Transplant patient or patient on transplant list~* Patient under nasal oxygen or under noninvasive ventilation~* Pregnant woman~* Breast-feeding~* No Social security affiliation~* Informed consent non obtained at enrollment for all patients (consent of minor's parent for children)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin nebulized nasally (Type: EXPERIMENTAL): Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
- Physiologic serum nebulized nasally (Type: PLACEBO_COMPARATOR): Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).